

## Applications

Crystallization screen for proteins, peptides, nucleic acids and water soluble small molecules where salt is the preferred primary crystallization reagent.

## Features

- Salt and pH only sparse matrix crystallization screen
- Samples pH 4.6 – 8.5
- 22 unique salts versus concentration and pH
- Preformulated, ready to screen
- Compatible with MicroBatch, Vapor Diffusion, Liquid & Gel Diffusion methods

## General Description

SaltRx™ was developed by Hampton Research as a salt only crystallization screen matrix. Salt is the single primary crystallization reagent (precipitant) utilized in SaltRx. Based on a design of 96 conditions, the screen evaluates a broad portfolio of crystallization salts of varying concentration and pH. The selection of salts, the concentration of salts and pH was determined by data mining the BMCD<sup>10</sup>, additional crystallization reports in the literature and internal crystallization trials. Based on crystallization results in the BMCD, and subsequent literature, up to 35% of protein crystallizations involve salt as the primary crystallization reagent. SaltRx is to be used as a primary crystallization screen when salt and ionic strength is desired or suspected as an appropriate crystallization reagent. SaltRx is also useful as a secondary screen when salt only reagents/conditions from screens such as Index™, Crystal Screen™, and Grid Screen Ammonium Sulfate™ produce crystals and further screening for additional salt conditions is desired. As SaltRx does not contain volatile organics the screen is compatible with MicroBatch, Vapor Diffusion, Liquid and Gel diffusion crystallization methods. SaltRx may also be used for microdialysis crystallization in conjunction with MicroDialysis Buttons.

## Sample Preparation

The macromolecular sample should be homogenous, as pure as is practically possible (>95%) and free of amorphous and particulate material. Remove amorphous material by centrifugation or micro-filtration prior to use.

The recommended sample concentration is 5 to 25 mg/ml in dilute buffer (10 to 25 mM). The sample should be free of any unnecessary additives in order to observe the effect of the SaltRx variables. Ideally, the initial screen should be performed with a sample which has been dialyzed against dilute buffer (such as 25 mM sodium Hepes pH 7.0) although ligands, ions, reducing agents, or other additives may be present as required by the sample for solubility, stability, or activity.


## Performing The Screen

Since it is the most frequently reported method of crystallization, the following procedure describes the use of SaltRx with the Hanging Drop Vapor Diffusion method. SaltRx is also very compatible with the Sitting Drop, Sandwich Drop, MicroBatch, and Microdialysis methods. A complete description of the Hanging, Sitting, Sandwich Drop, Dialysis and other crystallization methods are available from the Hampton Research Crystal Growth 101 Library.

1. Prepare a VDX Plate™ (HR3-140) for Hanging Drop Vapor Diffusion by applying a thin bead of cover slide sealant to the upper edge of each of the 24 reservoirs. One may also use a Greased VDX Plate™ (HR3-170). Ninety-six reservoirs are to be prepared for a complete SaltRx. See Figure 1.

**Figure 1**

Cross section of a reservoir in the VDX plate.



2. Using a clean pipet tip, pipet 1 ml of SaltRx reagent 1 into reservoir A1. Discard the pipet tip, add a new pipet tip and pipet 1 ml of SaltRx reagent 2 into reservoir A2. Repeat the procedure for the remaining 94 SaltRx reagents using a clean pipet tip for each reagent so as to avoid reagent contamination and carry over.

3. Pipet 2 µl of the sample to the center of a clean, siliconized 22 mm diameter circle or square cover slide. See Figure 2.

**Figure 2**




4. Pipet 2 µl of SaltRx reagent 1 from reservoir A1 into the sample droplet and mix by aspirating and dispensing the droplet several times, keeping the tip in the drop during mixing to avoid foaming. See Figure 2.

5. Working quickly to minimize evaporation, invert the cover slide and droplet over reservoir A1 and seal the cover slide onto the edge of the reservoir. See Figure 3.

**Figure 3**

Inverted siliconized coverslip placed over the reservoir.



6. Repeat operations 3 through 5 for the remaining 95 SaltRx reagents.

7. If the quantity of sample permits, perform SaltRx in duplicate and incubate one set of plates at 4 °C and the second set at room temperature. Incubate and store the crystallization plates in a stable temperature environment free of vibration.

## Examine The Drop

Carefully examine the drops under a stereo microscope (10 to 100x magnification) immedi-

**Figure 4**  
Typical observations in a crystallization experiment.



ately after setting up the screen. Record all observations and be particularly careful to scan the focal plane for small crystals. Observe the drops once each day for the first week, then once a week thereafter. Records should indicate whether the drop is clear, contains precipitate, and/or crystals. It is helpful to describe the drop contents using descriptive terms. Adding magnitude is also helpful. Example: 4+ yellow/brown fine precipitate, 2+ small bipyramid crystals, clear drop, 3+ needle shaped crystals in 1+ white precipitate. One may also employ a standard numerical scoring scheme (Clear = 0, Precipitate = 1, Crystal = 10, etc). Figure 4 (on page 2) shows typical examples of what one might observe in a crystallization experiment.

### Interpreting SaltRx

Clear drops indicate that either the relative supersaturation of the sample and reagent is too low or the drop has not yet completed equilibration. If the drop remains clear after 3 to 4 weeks consider repeating the SaltRx condition and doubling the sample concentration. If more than 70 of the 96 SaltRx drops are clear consider doubling the sample concentration and repeating the entire screen.

Drops containing precipitate indicate that either the relative supersaturation of the sample and reagent is too high, the sample has denatured, or the sample is heterogeneous. To reduce the relative supersaturation, dilute the sample twofold and repeat the SaltRx condition. If more than 70 of the 96 SaltRx drops contain precipitate and no crystals are present, consider diluting the sample concentration in half and repeating the entire screen. If sample denaturation is suspect, take measures to stabilize the sample (add reducing agent, ligands, glycerol, salt, or other stabilizing agents). If the sample is impure, aggregated, or heterogeneous take measures to pursue homogeneity. It is possible to obtain crystals from precipitate so do not discard nor ignore a drop containing precipitate. If possible, examine drops containing precipitate under polarizing optics to differentiate precipitate from microcrystalline material.

If the drop contains a macromolecular crystal the relative supersaturation of the sample and reagent is appropriate for crystallization. The next step is to optimize the preliminary conditions (pH, salt type, salt concentration, precipitant type, precipitant concentration, sample concentration, temperature, additives, and other crystallization variables) which produced the crystal in order to improve crystal size and quality.

Compare the observations between the 4°C and room temperature incubation to determine the effect of temperature on sample solubility.

Different results in the same drops at different temperatures indicate that sample solubility is temperature dependent and that one should include temperature as a variable in subsequent screens and optimization experiments.

Retain and observe plates until the drops are dried out. Crystal growth can occur within 15 minutes or one year.

### SaltRx Formulation

SaltRx reagents are formulated using the highest purity chemicals, ultrapure water (18.2 Megohm-cm, 5 ppb TOC) and are sterile filtered using 0.22 micron filters into sterile containers (no preservatives added).

SaltRx reagents are readily reproduced using Hampton Research Optimize™ stock solutions of salts, polymers and buffers. Optimize stock reagents make reproducing SaltRx reagents fast, convenient and easy. Dilutions can be performed directly into the crystallization plate using Optimize stock reagents.

SaltRx reagents containing buffers are formulated by creating a 1.0 M stock buffer, titrated to the desired pH using hydrochloric acid or sodium hydroxide. The buffer is then diluted with the other reagent components and water. No further pH adjustment is required.

SaltRx reagents are stable at room temperature and are best used before the "Best If Used By" date on the kit tubes. To enhance reagent stability it is strongly recommended that SaltRx be stored at 4°C or -20°C.

If the sample contains phosphate, borate, or carbonate buffers it is possible to obtain inorganic crystals (false positives) when using SaltRx reagents containing divalent cations. To avoid false positives use phosphate, borate, or carbonate buffers at concentrations of 10 mM or less or exchange the phosphate, borate, or carbonate buffer with a more soluble buffer that does not complex with divalent cations such as sodium Hepes.

### References and Readings

1. Crystallization of nucleic acids and proteins, Edited by A. Ducruix and R. Giegé, The Practical Approach Series, Oxford Univ. Press, 1992.
2. Current approaches to macromolecular crystallization. McPherson, A. Eur. J. Biochem. 189, 1-23, 1990.
3. Sparse Matrix Sampling: a screening method for crystallization of proteins. Jancarik, J. and Kim, S.H. J. Appl. Cryst., 24,409-411, 1991.

4. Protein and Nucleic Acid Crystallization. Methods, A Companion to Methods in Enzymology, Academic Press, Volume 1, Number 1, August 1990.
5. A comparison of salts for the crystallization of macromolecules. McPherson, A. Protein Science, 10:418-422, 2001.
6. Entering a new phase: Using solvent halide ions in protein structure determination. Dauter, Z. and Dauter, M. Structure, Vol 9, R21-26, Feb 2001.
7. Efficiency Analysis of Screening Protocols Used in Protein Crystallization, B. W. Segelke, Journal of Crystal Growth 232 : 553-562 (2001).
8. A novel approach to crystallizing proteins under oil. D'Arcy, A. et al. Journal of Crystal Growth, (1996) 168, 175-180.
9. Chayen, N. et al, J. Appl. Cryst. (1990) 23, 297.
10. Gilliland, G.L., Tung, M., Blakeslee, D.M. and Ladner, J. 1994. The Biological Macromolecule Crystallization Database, Version 3.0: New Features, Data, and the NASA Archive for Protein Crystal Growth Data. Acta Crystallogr. D50 408-413.

## Technical Support

Inquiries regarding SaltRx reagent formulation, interpretation of screen results, optimization strategies and general inquiries regarding crystallization are welcome. Please e-mail, fax, or telephone your request to Hampton Research. Fax and e-mail Technical Support are available 24 hours a day. Telephone technical support is available 8:00 a.m. to 5:00 p.m. USA Pacific Standard Time.

Hampton Research  
34 Journey  
Aliso Viejo, CA 92656-3317 U.S.A.  
Tel: (949) 425-1321 • Fax: (949) 425-1611  
Technical Support e-mail: tech@hrmail.com  
Internet: www.hamptonresearch.com